Who is sponsoring NCT03255408?

NCT03255408 is sponsored by University of Calgary.

What drugs are being tested in NCT03255408?

Interventions in NCT03255408: Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep, Drug Lowering CBF and Intermittent Hypoxia Sleep, Placebo and Normoxia Sleep, Placebo and Intermittent Hypoxia Sleep.

What condition does NCT03255408 study?

NCT03255408 studies Obstructive Sleep Apnea of Adult, Hypoxia, Brain, Sleep Apnea, Sleep Disorder, Stroke, Blood Pressure, Endothelial Dysfunction, Oxidative Stress.

Is NCT03255408 still recruiting?

NCT03255408 is currently status unknown. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT03255408

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia

Status unknown Phase 1, PHASE2 Last updated 4 November 2022

What this trial tests

Phase 1, PHASE2 trial testing Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep in Obstructive Sleep Apnea of Adult in 12 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
30 December 2024

30 December 2024

Quick facts

Lead sponsor	University of Calgary
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	12
Start date	1 January 2023
Primary completion	30 December 2024
Estimated completion	30 December 2024

Drugs / interventions tested

Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep — full drug profile →
Drug Lowering CBF and Intermittent Hypoxia Sleep — full drug profile →
Placebo and Normoxia Sleep — full drug profile →
Placebo and Intermittent Hypoxia Sleep — full drug profile →

Conditions studied

Obstructive Sleep Apnea of Adult — all drugs for Obstructive Sleep Apnea of Adult →
Hypoxia, Brain — all drugs for Hypoxia, Brain →
Sleep Apnea — all drugs for Sleep Apnea →
Sleep Disorder — all drugs for Sleep Disorder →

Sponsor

University of Calgary

Who can join

Adults 18 to 45, any sex, with Obstructive Sleep Apnea of Adult or Hypoxia, Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea of Adult

Currently open trials in the same condition.

NCT06792188 — Smartwatch-Based AI Model for OSA Prediction (SWOSA) · recruiting
NCT06512779 — Developing a Treatment Clustering System for Obstructive Sleep Apnea Using Polysomnographic Physiological Signals · NA · recruiting
NCT06117579 — Effect of Inspiratory Muscle Training in Obstructive Sleep Apnea Syndrome. · NA · recruiting
NCT06447818 — Changes in Difficult Airway Markers After Surgery for Obstructive Sleep Apnoea Syndrome · recruiting
NCT06103630 — Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device · NA · recruiting

Other University of Calgary trials

Trials by the same sponsor.

NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03255408 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Calgary
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03255408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing